Table 1.
Demographics of study participants.
Table 2.
Characteristics of exit survey respondents (n = 903).
Table 3.
Race and ethnicity of exit survey respondents (n = 903).
Fig 1.
(A) Results from an exit survey question asking respondents to report through which methods they heard about IGI FAST. Respondents (n = 865) could select multiple answers. Abbreviations: IGI, Innovative Genomics Institute; UHS, University Health Services; UCB, University of California, Berkeley. (B) Of the 4,825 participants who enrolled, 992 did not give any samples, leaving 3,833 participants who gave 12,602 samples. A supply-chain shortage in week 11 caused a large number of samples (94% of samples collected in week 11) to go untested. For this reason, all 631 samples collected at the beginning of week 11 are excluded from the analysis of IGI FAST. One hundred eighty individuals only provided a sample during week 11, so they are excluded from the analysis of IGI FAST, leaving a final cohort of 3,653 participants that gave 11,971 samples in the studied weeks of IGI FAST.
Fig 2.
IGI FAST testing site workflow.
Our two testing sites followed the same workflow, which can be easily scaled to increase the throughput. Participants first checked in at station one, where they were screened for COVID-19 symptoms, potential contacts, and recent food or water consumption. At station 2, an appointment QR code was scanned, and a collection site worker created a test requisition. Participants then went to individually-staffed spitting stations, where they were supervised while giving their sample. At station 4, the tube was re-scanned, and participants confirmed their name and date of birth. At this point, the sample was dropped into a bag and left with the site worker. Parts of figure made using biorender.com.
Table 4.
Results and estimated community asymptomatic and presymptomatic prevalence by week.
Fig 3.
Sample characteristics throughout the study duration.
(A) The proportion of samples (n = 11,971) that returned with a specimen insufficient value decreased throughout the study. The teal-colored band represents samples that were rejected in a step before PCR analysis, such as an inability to pipette. (B) The mean (standard deviation) turn-around time decreased from 72.6 (68.8) hours in the first three weeks (n = 1,417) of the study to 45.9 (19.6) hours in the last three weeks (n = 2,665) of the study. Here, the blue bar depicts a 72-hour turn-around. The vertical red bar depicts the supply-chain shortage period that led to a temporary shutdown in testing. (C) A series of laboratory techniques (see Hamilton et al.) were deployed throughout the study to optimize the protocols, improving the sample rejection rate and turn-around time.
Fig 4.
Convenience of IGI FAST testing sites.
IGI FAST aimed to select testing sites on the University of California, Berkeley campus (A) near the buildings with the highest occupancy levels during the pandemic. Here, we represent occupancy based on answers given during enrollment. Residence halls and off-campus buildings are not depicted; neither are participants who did not report any building. Participants who provided a primary campus building were presumed to be approved to work in those buildings during the pandemic in this illustration. Participants who reported multiple campus buildings are counted multiple times in this illustration. (B) Overall, 82% of survey respondents who were approved to work on campus indicated that they worked within 10 minutes of the nearest testing site, excluding those who did not answer this question on the survey (n = 650). (C) When asked how long they would be willing to travel for regular surveillance testing, most survey respondents reported that they would be willing to travel six or more minutes for testing; however, many participants would be lost to travel times greater than ten minutes (n = 635).
Fig 5.
Participant reviews of IGI FAST.
IGI FAST was well-reviewed by participants. (A) To exit survey respondents who reported having done a respiratory swab-based SARS-CoV-2 test outside of IGI FAST (n = 515), IGI FAST was superior regarding tolerability and convenience. (B) When exit survey participants were asked how well various words described their experiences with the IGI FAST test, testing sites, or personnel, IGI FAST received favorable responses. (C) When asked whether participants would continue participating in a testing program using a nasal swab instead of IGI FAST, most respondents indicated a willingness to continue participation (n = 839). Of note, this question specified the hypothetical continued program would use nasal swabs instead of nasopharyngeal swabs, clarifying the difference between the two.
Fig 6.
(A) There were two waves of enrollment into the study–at the beginning of the study and again in the Fall when undergraduate students returned to the city for the beginning of the academic year. There was a wide variety of participation levels in the program. Here, participation rate represents the number of samples an individual gave divided by the number of possible appointments that individual could have made based on when they joined. The graphs here depict only active participants in the final cohort (n = 3,653). (B) The leading reasons for joining IGI FAST were elective (i.e., participants wanted regular viral testing, wanted to contribute to research, or had encouragement from friends/family/coworkers). 79% of the 865 respondents who completed this question reported more than one reason. (C) The majority (77%) of the total (n = 865) participants reported solely elective reasons for joining IGI FAST. Few (1%) reported imposed or "one-off" reasons (i.e., worry about COVID-19 exposure or symptoms, pressure from others, requirement or pressure from employer/boss/supervisor, the fulfillment of travel requirements). One individual was excluded from this analysis because their response was unclassifiable. (D) Examples of stickers produced to facilitate the normalization of surveillance testing on campus through cultivating a sense of pride.